This is an HTML version of an attachment to the Official Information request 'Molnupiravir for Horses, Zebras & Donkeys - offspring born with no teeth & skull missing'.

10 December 2021
Micky Turner
Via email: [FYI request #17158 email]
Dear Micky
Request for information: Early treatment options for COVID-19
Thank you for your request dated 13 November 2021 under the Official Information Act 1982 
(OIA) for information relating to early treatment options for COVID-19. You wrote:
Can you please advise if you have organized the supply of and are offering people 
with Covid-19 any of the following:

Fluvoxamine 89%
Budesonide 81%
Vitamin D 81%
Vitamin A 79%
Quercetin 79%
Melatonin 78%
Zinc 74%
Povidone-Iodine 71%
Sotrovimab 67%
Ivermectin 67%
Vitamin C 43%
Aspirin 21%

I have included their early treatment efficacy % beside each one. This information can 
be found at

The Ministry of Health should also have enough Budesonide and inhalers for 100,000 

We have not explicitly organised supply of the medicines you have listed for the treatment of 
COVID-19; however, we intend to seek clinical advice from our COVID-19 Therapeutics 
Advisory Group 
about fluvoxamine in early 2022. We have also confirmed with the supplier of 
budesonide inhalers that it would be able to meet increased demand that may result from 
additional use for people with COVID-19. 
Medicines listed on the Pharmaceutical Schedule without restriction (open listed) can be 
prescribed for the treatment of any condition, including COVID-19, where a prescriber feels it 
is appropriate. However, patients may need to pay for the cost of the medicine if it is not 
listed on the Pharmaceutical Schedule for their condition.
2021-22-061; A1546175

Pharmac has secured supplies of medicines specifically for the treatment of COVID-19. 
Information about these medicines and Pharmac's response to COVID-19 is being updated 
regularly on our website.
We trust that this information answers your queries. We are making our information more 
freely available, so we now publish selected OIA responses (excluding personal details) on 
our website. Please get in touch with us if you have any questions about this.
Yours sincerely
Rachel Read
Manager, Policy and Government Services
2021-22-061; A1546175

Document Outline